Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction.
anakoinosis
communicative reprogramming
master modifiers
metastatic tumors
reprogramming information flux
systems biology
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
06
2019
accepted:
28
11
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
11
1
2020
Statut:
epublish
Résumé
The current approach to systemic therapy for metastatic cancer is aimed predominantly at inducing apoptosis of cancer cells by blocking tumor-promoting signaling pathways or by eradicating cell compartments within the tumor. In contrast, a systems view of therapy primarily considers the communication protocols that exist at multiple levels within the tumor complex, and the role of key regulators of such systems. Such regulators may have far-reaching influence on tumor response to therapy and therefore patient survival. This implies that neoplasia may be considered as a cell non-autonomous disease. The multi-scale activity ranges from intra-tumor cell compartments, to the tumor, to the tumor-harboring organ to the organism. In contrast to molecularly targeted therapies, a systems approach that identifies the complex communications networks driving tumor growth offers the prospect of disrupting or "normalizing" such aberrant communicative behaviors and therefore attenuating tumor growth. Communicative reprogramming, a treatment strategy referred to as anakoinosis, requires novel therapeutic instruments, so-called master modifiers to deliver concerted tumor growth-attenuating action. The diversity of biological outcomes following pro-anakoinotic tumor therapy, such as differentiation, trans-differentiation, control of tumor-associated inflammation, etc. demonstrates that long-term tumor control may occur in multiple forms, inducing even continuous complete remission. Accordingly, pro-anakoinotic therapies dramatically extend the repertoire for achieving tumor control and may activate apoptosis pathways for controlling resistant metastatic tumor disease and hematologic neoplasia.
Identifiants
pubmed: 31921665
doi: 10.3389/fonc.2019.01408
pmc: PMC6934003
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1408Informations de copyright
Copyright © 2019 Heudobler, Lüke, Vogelhuber, Klobuch, Pukrop, Herr, Gerner, Pantziarka, Ghibelli and Reichle.
Références
J Intern Med. 2015 Feb;277(2):248-259
pubmed: 25495071
Immunol Lett. 2020 Apr;220:88-96
pubmed: 30885690
Lancet. 2014 Feb 8;383(9916):558-63
pubmed: 24351321
Front Pharmacol. 2018 Jun 25;9:689
pubmed: 29988614
Haematologica. 2023 Oct 26;:
pubmed: 37881883
Oncotarget. 2016 May 17;7(20):29761-9
pubmed: 27105513
Cancer Res. 2010 Jul 1;70(13):5358-67
pubmed: 20516119
Front Oncol. 2013 Dec 12;3:304
pubmed: 24377088
Nat Med. 2011 Jul 03;17(7):860-6
pubmed: 21725296
Oncogene. 2013 Nov 7;32(45):5283-91
pubmed: 23178486
Nat Rev Genet. 2018 Mar;19(3):160-174
pubmed: 29279606
PLoS Comput Biol. 2014 Feb 06;10(2):e1003461
pubmed: 24516373
Science. 2002 Mar 1;295(5560):1662-4
pubmed: 11872829
Eur J Pharmacol. 2018 Sep 5;834:188-196
pubmed: 30031797
J Clin Oncol. 2017 Jul 10;35(20):2288-2298
pubmed: 28530852
Nature. 2006 Nov 30;444(7119):638-42
pubmed: 17136094
Arch Toxicol. 2018 Mar;92(3):1311-1322
pubmed: 29170806
Nat Commun. 2019 Apr 16;10(1):1787
pubmed: 30992437
N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
Nature. 2015 Sep 24;525(7570):543-547
pubmed: 26367798
Nature. 2011 Aug 10;476(7359):163-9
pubmed: 21833082
Clin Cancer Res. 2017 Jun 15;23(12):3181-3190
pubmed: 28232477
Pharmacol Res. 2017 Oct;124:20-33
pubmed: 28735000
Oncogene. 1999 Apr 1;18(13):2281-90
pubmed: 10327074
Nature. 2019 Oct;574(7779):532-537
pubmed: 31645730
Science. 2018 Nov 23;362(6417):911-917
pubmed: 30337457
Sci Rep. 2017 Oct 23;7(1):13812
pubmed: 29062084
Curr Opin Genet Dev. 2011 Feb;21(1):93-9
pubmed: 21251810
Med Oncol. 2017 Nov 2;34(12):192
pubmed: 29098441
Oncotarget. 2016 Apr 19;7(16):22245-56
pubmed: 26967243
Philos Trans R Soc Lond B Biol Sci. 2013 Sep 23;368(1629):20130111
pubmed: 24062587
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):E388-97
pubmed: 22308451
Front Pharmacol. 2018 Nov 13;9:1279
pubmed: 30483125
Sci Signal. 2010 Feb 23;3(110):ra13
pubmed: 20179271
Cancer Microenviron. 2008 Dec;1(1):159-70
pubmed: 19308694
Lancet. 2015 May 9;385(9980):1843-52
pubmed: 25862517
Lancet Oncol. 2019 Jan;20(1):57-73
pubmed: 30559051
Ecancermedicalscience. 2014 Jul 10;8:442
pubmed: 25075216
Immunity. 2008 Jul 18;29(1):21-32
pubmed: 18631454
Aging (Albany NY). 2015 Aug;7(8):525-6
pubmed: 26298432
J Clin Oncol. 2014 Oct 10;32(29):3242-8
pubmed: 25135997
Cell. 2014 Jul 3;158(1):185-197
pubmed: 24954535
Cell. 2009 Mar 20;136(6):1136-47
pubmed: 19303855
Mol Oncol. 2014 Sep 12;8(6):1095-111
pubmed: 25087573
Cancer Res. 1993 Jun 1;53(11):2498-501
pubmed: 8495411
BMC Med. 2017 Jul 18;15(1):133
pubmed: 28716075
Cell. 1995 Jan 27;80(2):237-48
pubmed: 7834743
Blood. 2019 Mar 28;133(13):1495-1506
pubmed: 30674471
Clin Haematol. 1975 Jun;4(2):331-51
pubmed: 1102191
Blood. 2013 Jul 25;122(4):542-9
pubmed: 23741012
Clin Cancer Res. 2013 Aug 1;19(15):4079-91
pubmed: 23785047
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Med Oncol. 2015 Jan;32(1):416
pubmed: 25476481
Clin Med (Lond). 2010 Feb;10(1):37-40
pubmed: 20408304
Cancer Microenviron. 2015 Aug;8(2):75-92
pubmed: 26259724
Science. 2015 May 22;348(6237):880-6
pubmed: 25999502
Nature. 2010 Apr 1;464(7289):678
pubmed: 20360718
Nature. 2017 Aug 17;548(7667):334-337
pubmed: 28783732
Br J Cancer. 2018 Jan;118(2):145-152
pubmed: 29337961
Immunity. 2011 Oct 28;35(4):441-4
pubmed: 22035836
Nat Rev Cancer. 2007 Apr;7(4):246-55
pubmed: 17384580
Cancer Lett. 2016 Sep 28;380(1):205-15
pubmed: 26272180
Ecancermedicalscience. 2015 May 21;9:541
pubmed: 26082798
Cancer Lett. 2017 Aug 1;400:293-304
pubmed: 28202353
Annu Rev Biochem. 2006;75:655-80
pubmed: 16756506
Oncotarget. 2016 Sep 20;7(38):60954-60970
pubmed: 27528232
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Phys Biol. 2011 Feb;8(1):015017
pubmed: 21301063
Adv Protein Chem Struct Biol. 2018;111:101-132
pubmed: 29459029
J Clin Oncol. 2015 Dec 1;33(34):4032-8
pubmed: 26460303
Genome Med. 2019 May 28;11(1):35
pubmed: 31138277
J Natl Cancer Inst. 2002 Mar 6;94(5):358-68
pubmed: 11880474
Blood. 1996 May 15;87(10):4358-67
pubmed: 8639796
Front Pharmacol. 2018 Nov 28;9:1357
pubmed: 30546308
J Clin Oncol. 2016 Dec 10;34(35):4261-4269
pubmed: 27903154
Nat Commun. 2014 Mar 26;5:3543
pubmed: 24667544
Mol Cancer Ther. 2010 Dec;9(12):3221-32
pubmed: 21159608
PLoS One. 2009 Nov 19;4(11):e7916
pubmed: 19936259
Front Biosci (Elite Ed). 2015 Jan 01;7(2):322-45
pubmed: 25553383
Front Oncol. 2015 Aug 31;5:196
pubmed: 26380225
N Engl J Med. 2008 Nov 27;359(22):2313-23
pubmed: 19038878
Molecules. 2018 Jun 19;23(6):
pubmed: 29921764
Nat Rev Cancer. 2017 Feb;17(2):116-130
pubmed: 27977008
Cell. 2009 Mar 6;136(5):823-37
pubmed: 19269363
Front Pharmacol. 2019 Feb 26;10:100
pubmed: 30863306
Cell. 2018 Apr 19;173(3):595-610.e11
pubmed: 29656894
J Hematol Oncol. 2017 Oct 2;10(1):157
pubmed: 28969692
Curr Pharmacol Rep. 2018;4(3):250-260
pubmed: 30363743
EMBO Rep. 2016 Nov;17(11):1516-1531
pubmed: 27702988
Front Pharmacol. 2019 Mar 26;10:287
pubmed: 30971926
Cancer Lett. 2018 Apr 1;418:10-19
pubmed: 29331412
Nature. 2015 Sep 17;525(7569):380-3
pubmed: 26331539
Semin Cancer Biol. 2018 Feb;48:78-90
pubmed: 28473253
JAMA Oncol. 2019 Jul 01;5(7):1020-1027
pubmed: 31145418
Pharmacol Ther. 2017 Jun;174:22-26
pubmed: 28167216
Cell Death Differ. 2015 Apr;22(4):526-39
pubmed: 25526085
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
JCO Clin Cancer Inform. 2019 Feb;3:1-11
pubmed: 30742485
Expert Opin Drug Discov. 2017 May;12(5):465-474
pubmed: 28277836
PeerJ. 2016 Jun 29;4:e2176
pubmed: 27413638
Oncotarget. 2019 Jan 22;10(7):785-797
pubmed: 30774780
Mol Cancer Res. 2009 Sep;7(9):1534-42
pubmed: 19723872
Mol Cell. 2015 Apr 16;58(2):362-70
pubmed: 25801169
Nat Commun. 2017 Dec 5;8(1):1940
pubmed: 29208897
J Cell Biol. 1993 Mar;120(5):1281-8
pubmed: 8436594
Neoplasia. 2015 Sep;17(9):716-722
pubmed: 26476079
Carcinogenesis. 2017 Apr 1;38(4):474-483
pubmed: 28334197
Nat Rev Clin Oncol. 2015 Aug;12(8):445-64
pubmed: 25850553
Proc Natl Acad Sci U S A. 2019 May 28;116(22):10674-10680
pubmed: 31040208
Cancer Prev Res (Phila). 2016 Dec;9(12):895-905
pubmed: 27913448
Dev Cell. 2009 Aug;17(2):279-89
pubmed: 19686688
Front Immunol. 2018 Apr 13;9:745
pubmed: 29706964
Interdiscip Toxicol. 2014 Jun;7(2):73-84
pubmed: 26109882
Ann Transl Med. 2018 Apr;6(8):144
pubmed: 29862233
Oncogene. 2016 Nov 24;35(47):6045-6052
pubmed: 27041560
J Natl Cancer Inst. 2000 Mar 1;92(5):418-23
pubmed: 10699072
Anticancer Res. 2017 Jul;37(7):3367-3377
pubmed: 28668824
Aging Cell. 2017 Aug;16(4):797-813
pubmed: 28514051
Semin Cancer Biol. 2016 Feb;36:3-17
pubmed: 26416465
Mol Cell Proteomics. 2019 May;18(5):936-953
pubmed: 30792264
Cell Death Dis. 2016 Feb 04;7:e2087
pubmed: 26844701
Cell Death Differ. 2012 Jul;19(7):1208-19
pubmed: 22261616
J Cell Biol. 2017 Jan 2;216(1):31-40
pubmed: 28031422
Cell. 2017 Feb 9;168(4):629-643
pubmed: 28187285
PLoS One. 2013;8(1):e54968
pubmed: 23372804
Immunity. 2008 Aug 15;29(2):193-204
pubmed: 18701083
Cancer. 2017 May 15;123(10):1791-1799
pubmed: 28026860
Mol Cell Proteomics. 2018 Feb;17(2):290-303
pubmed: 29196338
Int J Mol Sci. 2018 Nov 09;19(11):
pubmed: 30424016
Nat Rev Cancer. 2012 Feb 09;12(3):181-95
pubmed: 22318237
Int J Mol Sci. 2017 Apr 22;18(4):
pubmed: 28441737
Ecancermedicalscience. 2018 Dec 06;12:886
pubmed: 30679953
Nature. 2018 Sep;561(7724):473-478
pubmed: 30185910
Curr Pharm Des. 2016;22(44):6625-6644
pubmed: 27587198
Front Pharmacol. 2018 Nov 27;9:1380
pubmed: 30542286
Drug Discov Today. 2003 Dec 15;8(24):1121-7
pubmed: 14678738
Integr Biol (Camb). 2011 Jan;3(1):17-30
pubmed: 20944865
Cancer Microenviron. 2009 Sep;2 Suppl 1:227-37
pubmed: 19593676
Cancer Cell. 2019 Jan 14;35(1):17-32.e6
pubmed: 30645973
Methods Mol Biol. 2017;1513:101-117
pubmed: 27807833
Cancer Immunol Res. 2018 Nov;6(11):1375-1387
pubmed: 30143538
Nature. 2019 Jan;565(7739):312-317
pubmed: 30602793
Mol Cell Proteomics. 2017 Jan;16(1):86-99
pubmed: 27879288
Oncogene. 2016 Nov 17;35(46):5931-5941
pubmed: 27086930
Trends Cancer. 2016 Mar;2(3):144-158
pubmed: 28435907
Oncotarget. 2016 Sep 27;7(39):63189-63203
pubmed: 27527857
Exp Mol Med. 2018 Sep 21;50(9):1-10
pubmed: 30242145
Ann Oncol. 2016 Dec;27(12):2184-2195
pubmed: 27681864
Molecules. 2018 Apr 24;23(5):
pubmed: 29695137
Nature. 2017 Jul 27;547(7664):453-457
pubmed: 28678785
J Eur Acad Dermatol Venereol. 2016 Nov;30(11):e119-e121
pubmed: 26417987
Cancer Res. 2012 Dec 15;72(24):6512-23
pubmed: 23100468
Biomed Res Int. 2015;2015:845340
pubmed: 25866814
Clin Cancer Res. 2015 Feb 1;21(3):632-41
pubmed: 25056374
Cell Cycle. 2009 Mar 1;8(5):716-24
pubmed: 19221484
Mol Syst Biol. 2015 Feb 19;11(1):789
pubmed: 25699542
Nat Commun. 2019 Jan 28;10(1):470
pubmed: 30692544
Nature. 2015 Jan 8;517(7533):209-13
pubmed: 25470039
Eur J Pharmacol. 2018 Mar 15;823:19-26
pubmed: 29378193
Nat Rev Cancer. 2019 Feb;19(2):97-109
pubmed: 30578414
Blood. 2017 Mar 30;129(13):1802-1810
pubmed: 28115365
Oncology. 2012;82(5):249-60
pubmed: 22538363
Clin Cancer Res. 2019 Jul 1;25(13):4063-4078
pubmed: 30952635
J Cell Physiol. 2014 Nov;229(11):1595-606
pubmed: 24604522
Nat Rev Cancer. 2001 Oct;1(1):46-54
pubmed: 11900251
J Biosci. 2014 Apr;39(2):281-302
pubmed: 24736160
EMBO Mol Med. 2010 Mar;2(3):98-110
pubmed: 20201032
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Haematologica. 2015 Aug;100(8):e328-30
pubmed: 25840600
Clin Cancer Res. 2007 Jul 15;13(14):4042-5
pubmed: 17634527
Haematologica. 2017 Oct;102(10):1748-1757
pubmed: 28912173
Semin Radiat Oncol. 2013 Oct;23(4):288-95
pubmed: 24012343
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Ann Oncol. 2017 Dec 01;28(12):3070-3075
pubmed: 29045504
Future Oncol. 2018 Jun;14(13s):19-28
pubmed: 29989449
Cancer Res. 2010 Aug 1;70(15):6336-43
pubmed: 20647316
Mol Biosyst. 2015 Dec;11(12):3244-52
pubmed: 26448606
Curr Cancer Drug Targets. 2012 Jul;12(6):597-606
pubmed: 22463586
Cell. 2009 Dec 11;139(6):1069-83
pubmed: 19962179
Front Pharmacol. 2018 Nov 13;9:1307
pubmed: 30483138
PLoS One. 2018 Jun 21;13(6):e0198525
pubmed: 29927945
Nat Med. 2018 Aug;24(8):1157-1166
pubmed: 30038221
Cancer Cell. 2017 Sep 11;32(3):377-391.e9
pubmed: 28898698
Nat Med. 2006 Aug;12(8):925-32
pubmed: 16892036
Pathol Oncol Res. 2019 Oct;25(4):1269-1277
pubmed: 30220022
Haematologica. 2015 Jan;100(1):e4-6
pubmed: 25261094
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505
Leukemia. 2016 Oct;30(10):1987-1992
pubmed: 27133819
Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96
pubmed: 26106142
Cancer Res. 2014 Apr 15;74(8):2306-15
pubmed: 24556718